PMID- 25434712
OWN - NLM
STAT- MEDLINE
DCOM- 20150526
LR  - 20231213
IS  - 1873-2399 (Electronic)
IS  - 0301-472X (Linking)
VI  - 43
IP  - 3
DP  - 2015 Mar
TI  - Do human leukocyte antigen E polymorphisms influence graft-versus-leukemia after 
      allogeneic hematopoietic stem cell transplantation?
PG  - 149-57
LID - S0301-472X(14)00805-4 [pii]
LID - 10.1016/j.exphem.2014.11.007 [doi]
AB  - Hematopoietic-stem-cell transplantation (HSCT) is complicated by 
      histocompatibility-dependent immune responses such as graft-versus-host disease, 
      relapse, and graft rejection. The severity of these common adverse effects is 
      directly related to the degree of human leukocyte antigen (HLA) incompatibility. 
      In addition to the key role of classic HLA matching in influencing HSCT outcome, 
      several lines of evidence suggest an important role for nonclassic major 
      histocompatibility complex class I molecule, HLA-E. The interaction of HLA-E with 
      NKG2A, its main receptor on natural killer cells, modulates cell-mediated 
      cytotoxicity and cytokine production, an important role in innate immune 
      responses. In addition, the HLA-E molecule can present peptides to different 
      subtypes of T cells that may either support graft-versus-leukemia effects or be 
      involved in bridging innate and acquired immunity. To date, the role of HLA-E and 
      its polymorphisms in HSCT outcomes such as graft-versus-host disease, 
      transplant-related mortality, and improved survival has been published by a 
      number of groups. In addition, these data suggest an association between HLA-E 
      polymorphisms and relapse. Whether the engagement of the HLA-E molecule in the 
      modulation of donor T cells is involved in the graft-versus-leukemia effect, or 
      whether a different mechanism of HLA-E dependent reduction of relapse is 
      involved, requires further investigation.
CI  - Copyright (c) 2015 ISEH - International Society for Experimental Hematology. 
      Published by Elsevier Inc. All rights reserved.
FAU - Hosseini, Ehteramolsadat
AU  - Hosseini E
AD  - Blood Transfusion Research Center, High Institute for Research and Education in 
      Transfusion Medicine, Tehran, Iran; Department of Immunology, Alfred Medical 
      Research and Education Precinct, Monash University, Melbourne, Australia.
FAU - Schwarer, Anthony P
AU  - Schwarer AP
AD  - Department of Immunology, Alfred Medical Research and Education Precinct, Monash 
      University, Melbourne, Australia.
FAU - Ghasemzadeh, Mehran
AU  - Ghasemzadeh M
AD  - Blood Transfusion Research Center, High Institute for Research and Education in 
      Transfusion Medicine, Tehran, Iran. Electronic address: mehran1476@yahoo.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20141127
PL  - Netherlands
TA  - Exp Hematol
JT  - Experimental hematology
JID - 0402313
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - Graft vs Leukemia Effect/*genetics
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Histocompatibility Antigens Class I/*genetics
MH  - Humans
MH  - Leukocytes/immunology
MH  - *Polymorphism, Genetic
MH  - HLA-E Antigens
EDAT- 2014/12/02 06:00
MHDA- 2015/05/27 06:00
CRDT- 2014/12/02 06:00
PHST- 2014/05/27 00:00 [received]
PHST- 2014/11/16 00:00 [revised]
PHST- 2014/11/19 00:00 [accepted]
PHST- 2014/12/02 06:00 [entrez]
PHST- 2014/12/02 06:00 [pubmed]
PHST- 2015/05/27 06:00 [medline]
AID - S0301-472X(14)00805-4 [pii]
AID - 10.1016/j.exphem.2014.11.007 [doi]
PST - ppublish
SO  - Exp Hematol. 2015 Mar;43(3):149-57. doi: 10.1016/j.exphem.2014.11.007. Epub 2014 
      Nov 27.